Evidence map›Paper›PMID 27115610›Full record

ReviewMycopathologia2016

Lichtheimia Infection in a Lymphoma Patient: Case Report and a Brief Review of the Available Diagnostic Tools.

Stefan Zimmerli, Ralf Bialek, Igor W Blau, Andreas Christe, Cornelia Lass-Flörl, Elisabeth Presterl

Abstract readCase ReportsReview
PubMed Publisher
In one paragraph

Review in Mycopathologia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Stefan ZimmerliDepartment of Infectious Diseases, Bern University Hospital, University of Bern, 3010, Bern, Switzerland. stefan.zimmerli@insel.ch.
Ralf BialekLADR GmbH MVZ Dr. Kramer and Kollegen, Lauenburger Straße 67, 21502, Geesthacht, Germany.
Igor W BlauCharité University Hospital, Benjamin Franklin Campus, Hindenburgdamm 30, 12200, Berlin, Germany.
Andreas ChristeDepartment of Diagnostic, Interventional and Pediatric Radiology, Bern University Hospital, University of Bern, 3010, Bern, Switzerland.
Cornelia Lass-FlörlDivision of Hygiene and Medical Microbiology, Medical University, Schöpfstr. 41, 6020, Innsbruck, Austria.
Elisabeth PresterlMedical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We describe the case of a patient with a T-lymphoblastic lymphoma whose disseminated mucormycosis was diagnosed with delay, and we address the diagnostic and therapeutic decision-making process and review the diagnostic workup of patients with potential IFD. The diagnosis was delayed despite a suggestive radiological presentation of the patient's pulmonary lesion. The uncommon risk profile (T-lymphoblastic lymphoma, short neutropenic phases) wrongly led to a low level of suspicion. The diagnosis was also hampered by the lack of indirect markers for infections caused by Mucorales, the low sensitivity of both fungal culture and panfungal PCR, and the limited availability of species-specific PCR. A high level of suspicion of IFD is needed, and aggressive diagnostic procedures should be promptly initiated even in apparently low-risk patients with uncommon presentations. The extent of the analytical workup should be decided on a case-by-case base. Diagnostic tests such as the galactomannan and β-D-glucan test and/or PCR on biological material followed by sequencing should be chosen according to their availability and after evaluation of their specificity and sensitivity. In high-risk patients, preemptive therapy with a broad-spectrum mould-active antifungal agent should be started before definitive diagnostic findings become available.

Indexed as

beta-GlucansDiagnostic Tests, RoutineDNA, FungalFemaleHumansMiddle AgedMucoralesMucormycosisPolymerase Chain ReactionPrecursor Cell Lymphoblastic Leukemia-LymphomaProteoglycansSequence Analysis, DNAbeta-GlucansDNA, Fungalpolysaccharide-KProteoglycansDiagnosisEmerging risk groupsMolecular biologyMucoralesMucormycosis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.